Among the specific topics commanding healthcare professionals' (HCP) attention were the potential for Sanofi’s Dupixent in eosinophilic esophagitis, Amgen’s tezepelumab in uncontrolled asthma, and Lilly’s Olumiant in atopic dermatitis.

During Q4 earnings calls, biopharmaceutical companies reflected on the cumulative impact of the COVID-19 pandemic. An assessment of US-based physician sentiment (n=62) provides a useful ‘on-the-ground’ perspective to further examine these issues.

On International Women's Day, ZoomRxers #ChooseToChallenge any gender bias at the workplace. We commit to bringing about change and accelerating gender parity at the workplace.

Across multiple indications, physicians anticipate 2021 will be an exciting year for advancing treatments across autoimmune and auto-inflammatory conditions.In a study conducted by ZoomRx late December 2020, 107 practicing U.S. rheumatologists

Early stage data showcasing the potential of both genome editing using CRISPR and gene therapy in non-malignant hematological disorders captured attention during this year’s fully virtual ASH annual meeting.A highlight of

Having weathered many challenges in Q2 2020, biopharmaceutical firms, by and large, presented a case for optimism during Q3 2020 earnings calls. However, alongside this optimistic outlook were a number of voices expressing

Uma Sankar is a Software Development Lead in our Chennai office. She’s been at ZoomRx for over four years and has worked in software development for seven. Uma’s deep understanding of

Oncologists are growing accustomed to attending the field’s major meetings virtually, with AACR, ASCO, and now ESMO 2020 having gone fully digital.While the virtual format has undoubtedly impacted attendees’ experiences and

The prostate-specific antigen (PSA) score has become a critical post-diagnosis tool for oncologists as they discuss prostate cancer disease state with their patients along with their families and caregivers.Oncologist-patient relationships are based

Oncologists often develop individualized treatment plans to ensure patients are receiving care tailored to their situation. Here are factors influencing their decisions.

Despite the disruption and transition to a completely virtual format, 2020 was not an off-year for ASCO. Nearly all oncologists who attended this year’s ASCO Annual Meeting felt that it represented at

With the ASCO 2020 Annual Meeting just days away, oncologists are nearly universally planning to “attend” this year’s virtual meeting. However, their participation in the meeting will be less in real-time and

Often, traditional research doesn't answer all questions pertaining to clinical treatment decisions. Here's ZoomRx's new approach to address such questions.

Since 2018, the migraine treatment landscape has changed dramatically, with two new approvals in the month of February alone (Vyepti, Nurtec ODT). In light of these developments, we were curious about how migraine